Sugi Predict

Sugi Predict / Compounds / SCHEMBL4837150

SCHEMBL4837150

SCHEMBL4837150

CCOC(=O)C(=O)c1cccc2ncccc12

nearest known ligand 0.49

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NSD2 O96028 1/20 0.49
▸ CYP1A2 P05177 1/20 0.45
▸ CYP3A4 P08684 1/20 0.45
▸ CYP2D6 P10635 1/20 0.45
▸ MAPT P10636 1/20 0.45
▸ MAPK1 P28482 1/20 0.45
▸ CYP2C19 P33261 1/20 0.45
▸ MEN1 O00255 4/20 0.44
▸ KMT2A Q03164 4/20 0.44
▸ P2RX7 Q99572 1/20 0.43
▸ NR4A1 P22736 1/20 0.43
▸ ESR2 Q92731 1/20 0.43
▸ ALDH1A1 P00352 2/20 0.42
▸ HTT P42858 2/20 0.42
▸ LMNA P02545 1/20 0.42
▸ SMN1; SMN2 Q16637 1/20 0.42
▸ POLB P06746 1/20 0.41
▸ PABPC1 P11940 2/20 0.41
▸ EIF4H Q15056 2/20 0.41
▸ PKM P14618 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27605541 0.90 KMT2A (0.44) NSD2CYP3A4MAPTMEN1KMT2A
SCHEMBL5669102 0.85 TSHR (0.54) NSD2MAPTMEN1KMT2AALDH1A1
SCHEMBL18070708 0.84 MAPT (0.44) CYP1A2CYP3A4CYP2D6MAPTMAPK1
SCHEMBL4840028 0.84 NSD2 (0.45) NSD2CYP1A2CYP3A4CYP2D6MAPT
SCHEMBL4840021 0.84 NSD2 (0.45) NSD2CYP1A2CYP3A4CYP2D6MAPT
SCHEMBL23611791 0.83 NSD2 (0.44) NSD2CYP1A2CYP3A4CYP2D6MAPT
SCHEMBL3100232 0.82 NSD2 (0.43) NSD2CYP1A2CYP3A4CYP2D6MAPT
SCHEMBL13069262 0.82 NSD2 (0.43) NSD2CYP1A2CYP3A4CYP2D6MAPT
SCHEMBL3100238 0.81 NSD2 (0.45) NSD2CYP1A2CYP3A4CYP2D6MAPT
SCHEMBL18070716 0.80 MAPT (0.41) CYP1A2CYP3A4CYP2D6MAPTMAPK1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20260138987-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS INC (US) 2026-05-21 — — US disclosed
US-12565501-B2 Muscarinic acetylcholine M1 receptor antagonists CONTINEUM THERAPEUTICS, INC. (US) 2026-03-03 — — US disclosed
US-20250171455-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS INC (US) 2025-05-29 — — US disclosed
US-20230089921-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CONTINEUM THERAPEUTICS, INC. 2023-03-23 — — US disclosed
CN-114729044-A Muscarinic acetylcholine M1Receptor antagonists 帕珀莱恩医疗公司 2022-07-08 — — CN disclosed
WO-2021071843-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS Pipeline Therapeutics, Inc. (US) 2021-04-15 — — WO disclosed
WO-2021071843-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS Pipeline Therapeutics, Inc. (US) 2021-04-15 — — WO disclosed
US-7351822-B2 Serine protease inhibitors ELI LILLY AND COMPANY (US) 2008-04-01 — — US disclosed
US-7053078-B2 Serine protease inhibitors ELI LILLY AND COMPANY (US) 2006-05-30 — — US disclosed
US-6946467-B2 Serine protease inhibitors ELI LILLY AND COMPANY (US) 2005-09-20 — — US disclosed
US-20030055246-A1 Serine protease inhibitors PROTHERICS MOLECULAR DESIGN LIMITED (GB) 2003-03-20 — — US disclosed
EP-1289954-A1 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2003-03-12 — — EP disclosed
EP-1289953-A1 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2003-03-12 — — EP disclosed
EP-1289972-A1 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2003-03-12 — — EP disclosed
EP-1289950-A1 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2003-03-12 — — EP disclosed
US-20020151724-A1 Serine protease inhibitors ELI LILLY AND COMPANY 2002-10-17 — — US disclosed
WO-2001096304-A1 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2001-12-20 — — WO disclosed
WO-2001096303-A1 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2001-12-20 — — WO disclosed
WO-2001096296-A1 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2001-12-20 — — WO disclosed
WO-2001096323-A1 SERINE PROTEASE INHIBITORS ELI LILLY AND COMPANY (US) 2001-12-20 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20030055246-A1 Serine protease inhibitors CTRL, CPN1, LOXL1 NSD2 2172/4885CYP1A2 2353/4885CYP3A4 3210/4885
US-12565501-B2 Muscarinic acetylcholine M1 receptor antagonists CHRM1, CHRM2, CHRM3 NSD2 2179/4885CYP1A2 1141/4885CYP3A4 1234/4885
US-20230089921-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM2, CHRM3 NSD2 2047/4885CYP1A2 862/4885CYP3A4 1283/4885
US-20260138987-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM5, CHRM3 NSD2 1612/4885CYP1A2 1145/4885CYP3A4 1239/4885
US-20020151724-A1 Serine protease inhibitors SERPINE1, PRSS1, SERPINB1 NSD2 1512/4885CYP1A2 1342/4885CYP3A4 2553/4885
US-20250171455-A1 MUSCARINIC ACETYLCHOLINE M1 RECEPTOR ANTAGONISTS CHRM1, CHRM2, CHRM3 NSD2 2025/4885CYP1A2 865/4885CYP3A4 1279/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.